Clinical and Demographic Factors Associated With COVID-19, Severe COVID-19, and SARS-CoV-2 Infection in Adults
暂无分享,去创建一个
J. Kublin | A. Falsey | D. Follmann | P. Goepfert | K. Neuzil | Yunda Huang | J. Sadoff | A. Branche | B. Grinsztejn | H. Janes | I. Hirsch | M. Sobieszczyk | G. Gray | L. Baden | K. Kotloff | L. Dunkle | H. E. El Sahly | C. Gay | Lily Zhang | D. Graciaa | B. Leav | L. Corey | Deborah A. Theodore | T. Hatlen | P. Gilbert | Madhuchanda Choudhary | T. Babu | Jacqueline Miller | Raadhiya Osman | Samuel T Robinson
[1] J. Kublin,et al. Rapid Development of an Integrated Network Infrastructure to Conduct Phase 3 COVID-19 Vaccine Trials. , 2023, JAMA network open.
[2] Xing Wu,et al. B.1.351 SARS-CoV-2 Variant Exhibits Higher Virulence but Less Viral Shedding than That of the Ancestral Strain in Young Nonhuman Primates , 2022, Microbiology spectrum.
[3] D. Follmann,et al. Antinucleocapsid Antibodies After SARS-CoV-2 Infection in the Blinded Phase of the Randomized, Placebo-Controlled mRNA-1273 COVID-19 Vaccine Efficacy Clinical Trial , 2022, Annals of Internal Medicine.
[4] Benjamin Bowe,et al. Long-term cardiovascular outcomes of COVID-19 , 2022, Nature Medicine.
[5] N. Dreyer,et al. EpidemiologiCal POpulatioN STudy of SARS-CoV-2 in Lake CounTy, Illinois (CONTACT): Methodology and Baseline Characteristics of a Community-Based Surveillance Study , 2022, Infectious Diseases and Therapy.
[6] R. Grant,et al. Accounting for Social Risk Does not Eliminate Race/Ethnic Disparities in COVID-19 Infection Among Insured Adults: a Cohort Study , 2022, Journal of General Internal Medicine.
[7] S. Kahn,et al. The Incidence of Diabetes Among 2,777,768 Veterans With and Without Recent SARS-CoV-2 Infection , 2022, Diabetes care.
[8] L. Corey,et al. Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico , 2021, medRxiv.
[9] C. Mcevoy,et al. Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine , 2021, The New England journal of medicine.
[10] G. Tison,et al. Predictors of incident SARS-CoV-2 infections in an international prospective cohort study , 2021, BMJ Open.
[11] H. Ullum,et al. Seroprevalence of SARS-CoV-2 antibodies and reduced risk of reinfection through 6 months: a Danish observational cohort study of 44 000 healthcare workers , 2021, Clinical Microbiology and Infection.
[12] B. Zuckerman,et al. A prospective cohort study on the intersectionality of obesity, chronic disease, social factors, and incident risk of COVID-19 in US low-income minority middle-age mothers , 2021, International Journal of Obesity.
[13] Christine S. Smedley,et al. Difference in mortality among individuals admitted to hospital with COVID-19 during the first and second waves in South Africa: a cohort study , 2021, The Lancet Global Health.
[14] Derick R. Peterson,et al. Incidence of Respiratory Syncytial Virus Infection among Hospitalized Adults, 2017-2020. , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[15] S. Gómez-García,et al. Risk Factors for SARS-CoV-2 Infection, Pneumonia, Intubation, and Death in Northeast Mexico , 2021, Frontiers in Public Health.
[16] David A. Drew,et al. Diet quality and risk and severity of COVID-19: a prospective cohort study , 2021, Gut.
[17] A. Copas,et al. Incidence of SARS-CoV-2 infection according to baseline antibody status in staff and residents of 100 long-term care facilities (VIVALDI): a prospective cohort study , 2021, The Lancet Healthy Longevity.
[18] E. Zeggini,et al. From first to second wave: follow-up of the prospective COVID-19 cohort (KoCo19) in Munich (Germany) , 2021, BMC Infectious Diseases.
[19] H. Fennema,et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 , 2021, The New England journal of medicine.
[20] P. Klenerman,et al. SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN) , 2021, The Lancet.
[21] David A. Jolliffe,et al. Risk factors for developing COVID-19: a population-based longitudinal study (COVIDENCE UK) , 2021, Thorax.
[22] U. Fresán,et al. Hypertension and Related Comorbidities as Potential Risk Factors for COVID-19 Hospitalization and Severity: A Prospective Population-Based Cohort Study , 2021, Journal of clinical medicine.
[23] D. Weir,et al. SARS-CoV-2 seropositivity and subsequent infection risk in healthy young adults: a prospective cohort study , 2021, The Lancet Respiratory Medicine.
[24] J. Zein,et al. Association of Smoking and Cumulative Pack-Year Exposure With COVID-19 Outcomes in the Cleveland Clinic COVID-19 Registry. , 2021, JAMA internal medicine.
[25] K. Telle,et al. Factors associated with hospitalization, invasive mechanical ventilation treatment and death among all confirmed COVID-19 cases in Norway: Prospective cohort study , 2021, Scandinavian journal of public health.
[26] J. Mascola,et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine , 2020, The New England journal of medicine.
[27] G. Garber,et al. Epidemiology, clinical characteristics, household transmission, and lethality of severe acute respiratory syndrome coronavirus-2 infection among healthcare workers in Ontario, Canada , 2020, PloS one.
[28] D. Stuart,et al. Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers , 2020, The New England journal of medicine.
[29] E. Owusu-Dabo,et al. Epidemiological profile of SARS-CoV-2 among selected regions in Ghana: A cross-sectional retrospective study , 2020, PloS one.
[30] R. Clere-Jehl,et al. Clinical characteristics and risk factors associated with severe COVID-19: prospective analysis of 1,045 hospitalised cases in North-Eastern France, March 2020 , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[31] K. Dua,et al. Smoking and COVID-19: What we know so far , 2020, Respiratory Medicine.
[32] J. Soriano,et al. The impact of COVID-19 on patients with asthma , 2020, European Respiratory Journal.
[33] F. Khamis,et al. Characteristics of healthcare workers infected with COVID-19: A cross-sectional observational study , 2020, International Journal of Infectious Diseases.
[34] Hongjie Yu,et al. The disease burden of influenza beyond respiratory illness , 2020, Vaccine.
[35] H. J. Kim,et al. Effect of asthma and asthma medication on the prognosis of patients with COVID-19 , 2020, European Respiratory Journal.
[36] C. Gale,et al. Diabetes, glycaemic control, and risk of COVID-19 hospitalisation: Population-based, prospective cohort study , 2020, Metabolism.
[37] J. Rainey,et al. COVID-19 Among American Indian and Alaska Native Persons — 23 States, January 31–July 3, 2020 , 2020, MMWR. Morbidity and mortality weekly report.
[38] P. Sullivan,et al. Risk for COVID-19 infection and death among Latinos in the United States: examining heterogeneity in transmission dynamics , 2020, Annals of Epidemiology.
[39] Angelo Carfì,et al. Persistent Symptoms in Patients After Acute COVID-19. , 2020, JAMA.
[40] C. Torp‐Pedersen,et al. Association between male sex and outcomes of Coronavirus Disease 2019 (Covid‐19) – a Danish nationwide, register-based study , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[41] Joanna Ellis,et al. Risk factors for SARS-CoV-2 among patients in the Oxford Royal College of General Practitioners Research and Surveillance Centre primary care network: a cross-sectional study , 2020, The Lancet Infectious Diseases.
[42] John R. Mascola,et al. A strategic approach to COVID-19 vaccine R&D , 2020, Science.
[43] A. Shah,et al. A clinical risk score to identify patients with COVID-19 at high risk of critical care admission or death: An observational cohort study , 2020, Journal of Infection.
[44] Aaron van Dorn,et al. COVID-19 exacerbating inequalities in the US , 2020, The Lancet.
[45] Hemant Ishwaran,et al. Standard errors and confidence intervals for variable importance in random forest regression, classification, and survival , 2018, Statistics in medicine.
[46] D. Thompson,et al. A case-control study of risk factors for death from 2009 pandemic influenza A(H1N1): is American Indian racial status an independent risk factor? , 2015, Epidemiology and Infection.
[47] E. Walsh,et al. Respiratory syncytial virus infection in elderly and high-risk adults. , 2005, The New England journal of medicine.
[48] P. Grambsch,et al. Proportional hazards tests and diagnostics based on weighted residuals , 1994 .
[49] D. Thompson,et al. Deaths related to 2009 pandemic influenza A (H1N1) among American Indian/Alaska Natives - 12 states, 2009. , 2009, MMWR. Morbidity and mortality weekly report.